Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down Following Weak Earnings

Key Points

• Gyre Therapeutics experienced a significant drop in stock price, gapping down from $7.07 to $6.68 after reporting weaker than expected earnings, with an EPS of $0.02 compared to the estimated $0.03.
• The company reported revenue of $26.77 million for the quarter, falling short of the consensus estimate of $30.80 million.
• Despite the stock's downturn, several institutional investors increased their stakes in Gyre Therapeutics, indicating potential long-term confidence in the company.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $7.07, but opened at $6.68. Gyre Therapeutics shares last traded at $6.92, with a volume of 9,416 shares trading hands.

The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). Gyre Therapeutics had a return on equity of 9.73% and a net margin of 7.20%. The company had revenue of $26.77 million for the quarter, compared to the consensus estimate of $30.80 million.

Hedge Funds Weigh In On Gyre Therapeutics

Large investors have recently bought and sold shares of the business. Barclays PLC increased its stake in shares of Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after purchasing an additional 1,255 shares during the period. GAMMA Investing LLC increased its stake in shares of Gyre Therapeutics by 15,083.3% during the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after acquiring an additional 1,810 shares during the period. Wells Fargo & Company MN increased its stake in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after acquiring an additional 913 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Gyre Therapeutics by 18.7% during the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock valued at $127,000 after acquiring an additional 2,596 shares during the period. Finally, SBI Securities Co. Ltd. increased its stake in shares of Gyre Therapeutics by 22.1% during the first quarter. SBI Securities Co. Ltd. now owns 123,629 shares of the company's stock valued at $954,000 after acquiring an additional 22,390 shares during the period. Institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Stock Down 2.4%

The firm has a market cap of $646.94 million, a price-to-earnings ratio of 345.17 and a beta of 1.80. The stock's 50 day moving average is $7.67 and its 200 day moving average is $9.20.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.